F-SLOH
F-SLOH is a brain-penerant and orally active TFEB activator and amyloid-β inhibitor with an IC50 of 3.4 μM against amyloid-β. F-SLOH promotes nuclear translocation of TFEB, driving autophagy and lysosomal biogenesis. F-SLOH reduces amyloid-β oligomers and Tau aggregates via autophagy lysosomal degradation pathway. F-SLOH can be used for the research of Alzheimer’s disease.
For research use only. We do not sell to patients.
- CAS No.: 1620896-55-0
- Formula: C30H30ClFN2O3
- Molecular Weight:521.02
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
F-SLOH potently inhibits Aβ fibril formation in a cell-free biochemical assay with an IC50 of 3.4 μM[1].
F-SLOH (12.5-200 μM) exhibits low cytotoxicity in N2a-APP cells, with significant toxicity only observed at 200 μM[1].
F-SLOH (6.25-50 μM) dose-dependently reduces Aβ1-40 and Aβ1-42 levels in the media of N2a-APP cells[1].
F-SLOH (6.25-25 μM; 24 h) dose-dependently reduces full-length APP and CTFs protein levels in N2a-APP cells after 24 h of treatment[1].
F-SLOH reduces full-length APP levels in N2a-APP cells via a lysosomal degradation pathway[1].
F-SLOH (6.25-25 μM; 24 h) dose-dependently induces TFEB nuclear translocation in cultured microglial cells after 24 h of treatment[1].
F-SLOH (6.25-25 μM; 24 h) dose-dependently induces autophagy in HT-22 cells[1].
F-SLOH (6.25-25 μM; 24 h) dose-dependently promotes lysosomal biogenesis in HT-22 cells after 24 h of treatment[1].
F-SLOH (25 μM; 24 h) promotes autophagy flux and autophagosome-lysosome fusion in HT-22 cells stably expressing tf-LC3[1].
F-SLOH (24 h) increases lysosome number in HT-22 cells[1].
F-SLOH (6.25-25 μM;1-24 小时) inhibits the MAPK1/ERK2 pathway in HT-22 cells in both a dose-dependent and time-dependent manner[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:N2a-APP cells (N2a cells overexpressing APP695)
-
Concentration:6.25 μM; 12.5 μM; 25 μM
-
Incubation Time:24 h
-
Result:Dose-dependently reduced protein levels of full-length APP and its metabolite CTFs.
Caused significant reductions at all tested concentrations relative to control.
-
Cell Line:HT-22 cells
-
Concentration:6.25 μM; 12.5 μM; 25 μM
-
Incubation Time:24 h
-
Result:Dose-dependently increased LC3-II protein levels, indicating induction of autophagy.
Effect was comparable to the positive control Torin1.\nDose-dependently increased protein levels of LAMP1 and mature Cathepsin D, indicating promotion of lysosomal biogenesis.
Effect was comparable to the positive control Torin1.
-
Cell Line:HT-22 cells
-
Concentration:6.25 μM; 12.5 μM; 25 μM
-
Incubation Time:1 h; 2 h; 4 h; 6 h; 8 h; 24 h
-
Result:Dose-dependently reduced phospho-TFEB (S142) levels over 24 h.
Time-dependently reduced phospho-TFEB (S142) levels over 1-8 h.
Increased total TFEB levels, indicating TFEB dephosphorylation.
Dose-dependently reduced phospho-ERK1/2 and phospho-MEK levels over 24 h.
Time-dependently reduced phospho-ERK1/2 and phospho-MEK levels over 0-8 h.
Indicated inhibition of the MAPK1/ERK2 pathway.
Parmacokinetics
| Species | Dose | Route | Cmax | Tmax |
|---|---|---|---|---|
| Mice[1] | 20 mg/kg | i.p. | 81.134 ng/g | 1 h |
In Vivo
F-SLOH (10-20 mg/kg; p.o.; ad libitum; 6 months) dose-dependently reduces Alzheimer's disease pathology, improves cognitive function, and activates TFEB-mediated autophagy-lysosomal pathway in 3XTg-AD mice[1].
F-SLOH (10-20 mg/kg; 1 week) activates TFEB-mediated autophagy-lysosomal pathway in wild-type mice without causing body weight changes[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (heterozygous 5XFAD transgenic, 2 months old, male/female)[1]
-
Dosage:10 mg/kg; 20 mg/kg
-
Administration:i.p.; alternate days; 4 months
-
Result:Reduced levels of Aβ monomers (Aβ1-40, Aβ1-42), Aβ oligomers, and Aβ plaques in soluble and insoluble brain fractions.
Reduced full-length APP and its CTF metabolites.
Reduced astrocytic activation (GFAP staining) and microgliosis (Iba1 staining).
Increased hippocampal-dependent memory, as shown by prolonged freezing time in contextual fear conditioning tests relative to vehicle-treated mice.
Increased synaptic formation and postsynaptic density protein 95 (PSD-95)/synaptophysin expression.
Activated TFEB, increasing nuclear TFEB translocation, LC3B-II levels, LAMP1 levels, and mature cathepsin D levels to promote autophagy and lysosomal biogenesis.
Increased lysosome and autolysosome formation in hippocampal tissue.
-
Animal Model:B6;129 (female heterozygous 3XTg-AD transgenic, 6-12 months old, N=8 per group)[1]
-
Dosage:10 mg/kg; 20 mg/kg
-
Administration:p.o.; 6 months
-
Result:Reduced levels of Aβ monomers (Aβ1-40, Aβ1-42), Aβ oligomers, and Aβ plaques in soluble and insoluble brain fractions.
Reduced full-length APP and its CTF metabolites.
Reduced insoluble phosphorylated Tau (AT8, PHF1, CP13, MC1, HT7) levels and AT8/HT7-positive neuron load.
Reduced astrocytic activation (GFAP staining) and microgliosis (Iba1 staining).
Rescued learning impairment (shorter escape latency in Morris water maze), improved spatial memory (increased time spent in target quadrant during probe trial), and increased hippocampal-dependent memory (prolonged freezing time in contextual fear conditioning tests) relative to vehicle-treated mice.
Improved exploratory and locomotor function in open-field tests.
Increased dendritic spine density and postsynaptic density protein 95 (PSD-95)/synaptophysin expression.
Activated TFEB, increasing nuclear TFEB translocation, LC3B-II levels, LAMP1 levels, and mature cathepsin D levels to promote autophagy and lysosomal biogenesis.
-
Animal Model:C57BL/6 (wild-type, N=8 per group)[1]
-
Dosage:10 mg/kg; 20 mg/kg
-
Administration:1 week
-
Result:Increased nuclear TFEB translocation, reduced cytoplasmic TFEB levels, and increased LC3B-II, LAMP1, and mature cathepsin D levels in brain tissue to promote autophagy and lysosomal biogenesis.
Showed no significant change in mouse body weight.
Chemical Information
-
CAS No. 1620896-55-0
-
Molecular Weight 521.02
-
Formula C30H30ClFN2O3
-
SMILES
COCCOCCN1C2=CC=C(/C=C/C3=CC=[N+](CCO)C4=C3C=CC=C4)C=C2C5=CC(F)=CC=C51.[Cl-]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cytoplasmic-Nuclear Fractionated Protein Extraction
Cytoplasmic-nuclear fractionated protein extraction separates soluble cytoplasmic proteins from nuclear-enriched proteins by mild plasma-membrane permeabilization, differential centrifugation, washing of nuclei, and extraction of nuclear proteins for downstream immunoblotting or related molecular analysis. The readout is the relative abundance of a protein in cytoplasmic and nuclear fractions, commonly assessed by western blotting together with compartment markers such as tubulin or pyruvate kinase for cytoplasm and lamin, nucleoporin, hnRNP, H2AX, or Lamin B for nuclear fractions.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Amyloid: Congo Red Amyloid Staining
Congo red amyloid staining is a histochemical method used to detect extracellular amyloid deposits in tissue sections based on the affinity of Congo red dye for β-pleated sheet-rich protein aggregates. When bound to amyloid, Congo red produces characteristic apple-green birefringence under polarized light microscopy, which is widely regarded as a diagnostic feature of amyloid deposition in histopathology. The diagnostic principle relies on the combination of dye binding (congophilia) and optical anisotropy under polarized illumination, which distinguishes amyloid from most non-amyloid eosinophilic extracellular deposits in routine histological evaluation. Amyloid identification by Congo red staining remains a cornerstone in diagnostic pathology despite the availability of adjunct methods such as immunohistochemistry and mass spectrometry, particularly because of its ability to localize deposits directly within tissue architecture. The specificity of Congo red-positive deposits is incre
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
-
Alzheimer’s Disease Modeling
Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by a progressive decline in cognitive functions and loss of specific types of neurons and synapses. Alzheimer's symptoms can be simulated in mice by injecting drugs (such as Aβ) or genetically modified.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)